NCT06444399View on ClinicalTrials.gov

Deucravacitinib (BMS-986165) for Pityriasis Rubra Pilaris

PHASE2RecruitingINTERVENTIONAL

Enrollment

12

Participants

Timeline

Start Date

July 29, 2024

Primary Completion Date

January 1, 2026

Study Completion Date

July 1, 2026

Conditions

Pityriasis Rubra Pilaris

Interventions

DRUG

Deucravacitinib

6 mg administered orally twice daily for 24 weeks.

Trial Locations (1)

85259

RECRUITING

Mayo Clinic in Arizona, Scottsdale

Sponsors

Lead Sponsor

All Listed Sponsors

lead

Mayo Clinic

OTHER

NCT06444399 - Deucravacitinib (BMS-986165) for Pityriasis Rubra Pilaris | Biotech Hunter | Biotech Hunter